Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / GRIN Therapeutics, Inc.

Clinicaltrial registered17 Nov 2026

GRIN Therapeutics, Inc.

17 Nov 2026: Trial registered · A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
17 Nov 2026
Title
A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants
Conditions
GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07941206
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at GRIN Therapeutics, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for GRIN Therapeutics, Inc. in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.